128 related articles for article (PubMed ID: 27710813)
1. Potential clinical indications for a CCK
Boyce M; Lloyd KA; Pritchard DM
Curr Opin Pharmacol; 2016 Dec; 31():68-75. PubMed ID: 27710813
[TBL] [Abstract][Full Text] [Related]
2. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
[TBL] [Abstract][Full Text] [Related]
3. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
[TBL] [Abstract][Full Text] [Related]
4. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
5. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.
Boyce M; Warrington S; Black J
Br J Clin Pharmacol; 2013 Nov; 76(5):689-98. PubMed ID: 23432534
[TBL] [Abstract][Full Text] [Related]
6. Randomised trial of the effect of a gastrin/CCK
Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
[TBL] [Abstract][Full Text] [Related]
7. Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer.
Morton M; Prendergast C; Barrett TD
Trends Pharmacol Sci; 2011 Apr; 32(4):201-5. PubMed ID: 21397342
[TBL] [Abstract][Full Text] [Related]
8. Reflections on some pilot trials of gastrin receptor blockade in pancreatic cancer.
Black JW
Eur J Cancer; 2009 Feb; 45(3):360-4. PubMed ID: 19131241
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.
Takaishi S; Cui G; Frederick DM; Carlson JE; Houghton J; Varro A; Dockray GJ; Ge Z; Whary MT; Rogers AB; Fox JG; Wang TC
Gastroenterology; 2005 Jun; 128(7):1965-83. PubMed ID: 15940630
[TBL] [Abstract][Full Text] [Related]
10. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
Boyce M; Moore AR; Sagatun L; Parsons BN; Varro A; Campbell F; Fossmark R; Waldum HL; Pritchard DM
Br J Clin Pharmacol; 2017 Mar; 83(3):466-475. PubMed ID: 27704617
[TBL] [Abstract][Full Text] [Related]
11. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
[TBL] [Abstract][Full Text] [Related]
12. Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.
Aasarød KM; Ramezanzadehkoldeh M; Shabestari M; Mosti MP; Stunes AK; Reseland JE; Beisvag V; Eriksen EF; Sandvik AK; Erben RG; Schüler C; Boyce M; Skallerud BH; Syversen U; Fossmark R
J Endocrinol; 2016 Aug; 230(2):251-62. PubMed ID: 27325243
[TBL] [Abstract][Full Text] [Related]
13. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.
Boyce M; Thomsen L
Scand J Gastroenterol; 2015 May; 50(5):550-9. PubMed ID: 25665655
[TBL] [Abstract][Full Text] [Related]
14. Gastrin receptor pharmacology.
Dockray GJ; Moore A; Varro A; Pritchard DM
Curr Gastroenterol Rep; 2012 Dec; 14(6):453-9. PubMed ID: 22983899
[TBL] [Abstract][Full Text] [Related]
15. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.
Boyce M; Warrington S
Br J Clin Pharmacol; 2013 Nov; 76(5):680-8. PubMed ID: 23432415
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation.
Kidd M; Modlin IM; Black JW; Boyce M; Culler M
Regul Pept; 2007 Oct; 143(1-3):109-17. PubMed ID: 17531331
[TBL] [Abstract][Full Text] [Related]
17. JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.
Morton MF; Barrett TD; Freedman J; Li L; Rizzolio MC; Prendergast CE; Wu X; Moreno V; Pyati J; Figueroa K; Cagnon L; Lagaud G; Ver Donck L; Ghoos E; Allison B; Rabinowitz MH; Shankley NP
J Pharmacol Exp Ther; 2011 Jul; 338(1):328-36. PubMed ID: 21493750
[TBL] [Abstract][Full Text] [Related]
18. The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development.
Kidd M; Siddique ZL; Drozdov I; Gustafsson BI; Camp RL; Black JW; Boyce M; Modlin IM
Regul Pept; 2010 Jun; 162(1-3):52-60. PubMed ID: 20144901
[TBL] [Abstract][Full Text] [Related]
19. Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1.
Lloyd KA; Moore AR; Parsons BN; O'Hara A; Boyce M; Dockray GJ; Varro A; Pritchard DM
Oncotarget; 2016 Jul; 7(29):45462-45478. PubMed ID: 27323780
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of cholecystokinin-2 receptor promotes the progression of colon cancer through activation of focal adhesion kinase.
Yu HG; Tong SL; Ding YM; Ding J; Fang XM; Zhang XF; Liu ZJ; Zhou YH; Liu QS; Luo HS; Yu JP
Int J Cancer; 2006 Dec; 119(12):2724-32. PubMed ID: 16998832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]